Milan 2012 Programme Registration Exhibition Hotels Exhibitor Listing Satellite Meetings Visa Information
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Clinical evaluation of the treatment of myopic presbyopes with an excimer presbyopic LASIK procedure: 6 month follow-up

Poster Details

First Author: M.Cesena MEXICO

Co Author(s):    E. Barragan              

Abstract Details


Evaluation of the safety and efficacy of treating myopic presbyopes with a new presbyopic excimer LASIK procedure.


Laser Ocular Hidalgo, Monterrey, Mexico


: In this single centre, multi-surgeon evaluation, the non-dominant eye of 30 myopic presbyopic patients underwent a monolateral treatment with the SUPRACOR LASIK procedure using the Technolas 217P excimer laser (Technolas Perfect Vision). Where necessary, the fellow eye was treated with a standard LASIK. Uncorrected near and distance visual acuity (UNVA, UDVA) and best corrected distance visual acuity (BCDVA), safety, refraction and a patient questionnaire were evaluated. The follow-up period was 6 months.


: The mean patient age was 48.7 years (range: 45-53 years), pre-operative mean refractive spherical equivalent (MRSE) was -2.26D and mean cylinder of 0.75D. At 6 months follow-up, MRSE is -0.71D, stable after 1 month, and mean cylinder is -0.49D. For monocular UNVA, 73% see 0.8,compared with 53% pre-operatively. 82% have binocular UNVA of 0.8. Monocular UDVA improves from 10% at 20/32 pre-operatively to 93% at 20/32 at 6 months post-op. 100% have binocular UDVA of 1.0. 97% of patients have BCDVA of 1.25. The patient questionnaire revealed a high level of patient satisfaction.


: Six month data on myopic presbyopes treated with the Supracor LASIK procedure find it is a safe and effective treatment. There is a good level of spectacle independence and patient satisfaction. FINANCIAL DISCLOSURE?: ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous

loading Please wait while information is loading.